Clinical Trials Logo
  1. Home
  2. Molluscum Contagiosum
  3. NCT05634460

Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum

Molluscum Contagiosum Clinical Trial

Official title:
Comparison of 5% Potassium Hydroxide With 10% Potassium Hydroxide Solution in Treatment of Molluscum Contagiosum

Clinical Trial Summary

Molluscum is a virus-related skin infestation which is commonly seen among children. Molluscipox virus, the largest human virus, causes it. MC typically manifests as a single or multiple dome-shaped, shiny, pearly white papules with a central dimple. In immunocompetent individuals, spontaneous resolution usually occurs within 18 months; however, the lesion may persist for several years. Asymptomatic lesions are common. It is also linked to a high risk of transmission and an increasing prevalence in global populations1-2. Patients may receive therapy for social and cosmetic reasons, and also to avoid spreading disease to others. Numerous modalities are currently available, including Potassium hydroxide, curettage, cryotherapy, disinfected needle pricking, photodynamic therapy, laser, salicylic acid, glycolic acid etc3-4. Potassium hydroxide (KOH) is a topical treatment for Molluscum contagiosum. Dermatologists routinely use potassium hydroxide (KOH) in varying concentrations to identify fungal elements. Because it is a strong alkali with keratolytic characteristics, variable concentrations given for management of MC. Because it is inexpensive and widely accessible, it has the potential to be a useful method for treating for MC in resource-constrained countries5-6. The purpose of this study is to examine two varied concentrations of Potassium hydroxide (5%-KOH vs 10%-KOH) among MC patients in order to determine the most effective KOH concentration to manage Molluscum Contagiosum among children.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05634460
Study type Interventional
Source Combined Military Hospital Abbottabad
Contact
Status Completed
Phase Phase 1
Start date March 1, 2022
Completion date August 31, 2022
View Details
See also
  Status Clinical Trial Phase
Completed NCT03017846 - Safety and Efficacy of Topical Cantharidin for the Treatment of Molluscum Contagiosum, Phase 2 Phase 2
Recruiting NCT05937672 - Cold Atmospheric Plasma Device Extension Study Phase 3
Completed NCT04535531 - A Phase 3 Molluscum Contagiosum Efficacy and Safety Study Phase 3
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Completed NCT05897112 - Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum Phase 1
Withdrawn NCT05536882 - MC RCT - BPO vs Adapalene Phase 3
Completed NCT03377790 - Cantharidin Application in Molluscum Patients-1 Phase 3
Completed NCT01348386 - Efficacy and Tolerance of Potassium Hydroxide (10% and 15%) in Molluscum Contagiosum Phase 2/Phase 3
Completed NCT03186378 - Evaluation of Systemic Exposure to VP-102 in Subjects With Molluscum Contagiosum. Phase 2
Completed NCT03927716 - A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) Phase 3
Recruiting NCT04476186 - The Effectiveness of Oral Acyclovir in the Treatment of Molluscum Contagiosum in Children N/A
Completed NCT03927703 - A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC Phase 3
Completed NCT02665260 - Safety and Efficacy Study of Topical Cantharidin for the Treatment of Molluscum Contagiosum Phase 2
Completed NCT03436615 - A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum Phase 2
Recruiting NCT02759900 - Using a Cold Atmospheric Plasma Device to Treat Skin Disorders N/A
Recruiting NCT05680181 - Study of a Cohort of Children With Molluscum Contagiosum (MC) Treated With a 5% Solution of Potassium Hydroxide (Molutrex®) Applied Locally to the Skin
Completed NCT03077750 - A Study of VBP-245 in Pediatric Patients With Molluscum Contagiosum Phase 2
Terminated NCT02024581 - A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) for the Treatment of Molluscum Contagiosum Phase 2
Completed NCT03377803 - Cantharidin Application in Molluscum Patients Phase 3
Withdrawn NCT03336372 - Picato for the Treatment of Molluscum Contagiosum in Immunocompromised Patients Early Phase 1